Read our COVID-19 research and news.

Webinar Technology

Proteogenomic strategies to advance drug development and precision medicine

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Proteogenomic strategies to advance drug development and precision medicine

Recorded 06 September 2017


The genomics era has had a profound impact on life science research, leading to significant developments such as the use of expression quantitative trait loci (eQTLs), which link polymorphisms in single genes to quantifiable changes in gene expression associated with specific diseases. As the end products and biological effectors of gene expression, proteins are crucial for improving our understanding of human biology, developing new and better drugs, and advancing precision medicine. Proteomics technologies have lagged behind their genomics counterparts, but recent breakthroughs are now combining these methods in powerful ways. The journey to clinical utility, however, remains challenging. Association of a protein biomarker with any given disease process, for example, needs to be assessed in terms of disease-independent, confounding factors that may modulate protein expression levels among different individuals. Moreover, understanding whether an associated protein is causally involved in (or merely reflects) a disease process is extremely valuable information for identifying new drug targets. Our panelists will discuss how multi-omics and epidemiological approaches are accelerating important advances in the use of protein biomarkers for clinical research and pharmaceutical development.


During the webinar, the speakers will:

•             Discuss how covariates (genetic, environmental, and clinical) can affect the levels of potential biomarkers

•             Explore the use of covariate modeling to establish personally normalized plasma protein profiles (PNPPP) to reduce non-disease-related variation and maximize clinical potential

•             Describe how protein quantitative trait loci (pQTLs) can provide insights into disease biology and improve the efficiency of drug development

•             Answer your questions during the live broadcast!

This Webinar will last for approximately 60 minutes.

Speaker bios

Anders Mälarstig, Ph.D.

Stockholm, Sweden

Dr. Mälarstig received his M.S. in molecular biology and Ph.D. in cardiovascular genetics from Uppsala University in Sweden in 2001 and 2006, respectively. He did his postdoctoral training at the Karolinska Institutet in Stockholm, where he worked on translational studies of cardiovascular genetics, combining wet-lab research with large, population-based studies. In 2009 he joined Pfizer, where he is now director of Human Genetics and Computational Biomedicine. He has combined this work with being a senior researcher at Cambridge University and codirector of the Pfizer/Cambridge University Centre for Cardiovascular Genomics (2011–2013), and, since 2014, a position as senior researcher at the Karolinska Institutet. In his current role, he combines population research and functional genomics strategies to inform drug development from preclinical through phase 3 trials. Specifically, he is responsible for developing and applying strategies for new drug targets and precision medicine. As such, he has extensive experience working in international academic consortia and public–private partnerships.

Ulf Gyllensten, Ph.D.

Uppsala University
Uppsala, Sweden

Dr. Gyllensten received his Ph.D. from the Department of Genetics at Stockholm University in Sweden and his postdoctoral training at the University of California, Berkeley in the Department of Biochemistry. In 1987 he joined Cetus Corporation in California before returning to Sweden as an assistant professor in the Department of Medical Genetics at the University of Uppsala. He is now a full professor in Medical Molecular Genetics in the Department of Immunology, Genetics and Pathology at the University of Uppsala. He has cofounded two companies, Decipher Genetics AB and Quantovir AB, and holds patents for several molecular biology methods. His research interests include the molecular underpinnings of cervical cancer (including developing genetic screens), the identification of the genetic determinants of quantitative traits in humans, and the application of massively parallel sequencing technology for understanding the genetics of complex disease. He has over 250 publications in international, peer-reviewed journals.

Sean Sanders, Ph.D.

Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here